Erythropoiesis-stimulating agents in critically Ill trauma patients: A systematic review and meta-analysis

Annals of Surgery

Volumn 265, Issue 1, 2017, Pages 54-62

  French, Craig J ^a,c,g   Glassford, Neil J ^b,c   Gantner, Dashiell ^a,c   Higgins, Alisa M ^c   Cooper, David James ^c,d   Nichol, Alistair ^c,e   Skrifvars, Markus B ^c,h   Imberger, Georgina ^a   Presneill, Jeffrey ^c,f   Bailey, Michael ^c   Bellomo, Rinaldo ^b,c,g  

^a WESTERN HEALTH   (Australia)

^b AUSTIN HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d Department of Intensive Care ^*  (Australia)

^e ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Critical illness; Epoetin alfa; Erythropoiesis stimulating agents; Trauma

Indexed keywords

ANTIANEMIC AGENT; RECOMBINANT ERYTHROPOIETIN;

ACUTE HEART INFARCTION; CEREBROVASCULAR ACCIDENT; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DISABILITY; ERYTHROCYTE TRANSFUSION; GLASGOW OUTCOME SCALE; HEART ARREST; HUMAN; LUNG EMBOLISM; META ANALYSIS; MORTALITY RISK; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; SURVIVAL; SYSTEMATIC REVIEW; THROMBOSIS; TRAUMATIC BRAIN INJURY; CRITICAL ILLNESS; MORTALITY; STATISTICAL MODEL; TREATMENT OUTCOME; WOUNDS AND INJURIES;

CRITICAL ILLNESS; HEMATINICS; HUMANS; MODELS, STATISTICAL; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 84963674134     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001746     Document Type: Review

References (40)

1. Peden M, McGee K, Sharma G. The injury chart book: A graphical overview of the global burden of injuries. World Health Organization; 2002.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3: E442.
3. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem. 1977; 252: 5558-5564.
4. Solling C. Organ-protective and immunomodulatory effects of erythropoietin: An update on recent clinical trials. Basic Clin Pharmacol Toxicol. 2012; 110: 113-121.
5. Lu D, Mahmood A, Qu C, et al. Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J Neurotraum. 2005; 22: 1011-1017.
6. Yatsiv I, Grigoriadis N, Simeonidou C, et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J. 2005; 19: 1701-1703.
7. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. New Engl J Med. 2007; 357: 965-976.
8. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA. 2002; 288: 2827-2835.
9. Napolitano LM, Fabian TC, Kelly KM, et al. Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. J Trauma. 2008; 65: 285-297.
10. Nichol A, French CJ, Little L, et al. Erythropoietin in traumatic brain injury. Lancet. 2015; 386: 2499-2506.
11. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. New Engl J Med. 2006; 355: 2085-2098.
12. Robertson CS, Hannay HJ, Yamal JM, et al. Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: A randomized clinical trial. JAMA. 2014; 312: 36-47.
13. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2011.
14. Thorlund K, Devereaux PJ,Wetterslev J, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol. 2009; 38: 276-286.
15. Thorlund K, Engstrøm J, Wetterslev J, et al. User Manual for Trial Sequential Analysis (TSA). Copenhagen Trial Unit; 2011.
16. Wetterslev J, Thorlund K, Brok J, et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008; 61: 64-75.
17. Turner RM, Bird SM, Higgins JP. The impact of study size on meta-analyses: Examination of underpowered studies in Cochrane reviews. PloS One. 2013; 8: E59202.
18. Wetterslev J, Thorlund K, Brok J, et al. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Med Res Methodol. 2009; 9: 86.
19. Brok J, Thorlund K, Wetterslev J, et al. Apparently conclusive meta-analyses may be inconclusive: Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol. 2009; 38: 287-298.
20. Gerasimov LV, Yu S, Moroz VV, et al. Use of erythropoietin in patients with injury and blood loss. General Reanimatol. 2012; 8: 11-17.
21. Luchette FA, Pasquale MD, Fabian TC, et al. A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: The Long Term Trauma Outcomes Study. Am J Surg. 2012; 203: 508-516.
22. Abrishamkar S, Safavi M, Honarmand A. Effect of erythropoietin on Glasgow Coma Scale and Glasgow Outcome Sale in patient with diffuse axonal injury. J Res Med Sci. 2012; 17: 51-56.
23. Aloizos S, Evodia E, Gourgiotis S, et al. Neuroprotective effects of erythropoietin in patients with severe closed brain injury. Turk Neurosurg. 2015; 25: 552-558.
24. Nirula R, Diaz-Arrastia R, Brasel K et al. Safety and efficacy of erythropoietin in traumatic brain injury patients: A pilot randomized controlled trial. Crit Care Res Pract 2010; Article ID 209848. Available from Hindawi Publishing Corporation, New Youk, NY. Accessed November 2 2015.
25. Evans JA, van Wessem KJ, McDougall D, et al. Epidemiology of traumatic deaths: Comprehensive population-based assessment. World J Surg. 2010; 34: 158-163.
26. Cherian L, Goodman JC, Robertson C. Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. J Pharmacol Exp Ther. 2007; 322: 789-794.
27. Ponce LL, Navarro JC, Ahmed O, et al. Erythropoietin neuroprotection with traumatic brain injury. Pathophysiology. 2013; 20: 31-38.
28. KaukonenKM,BaileyM,Ady B, et al.Arandomised controlled trial of standard transfusion versus fresher red blood cell use in intensive care (TRANSFUSE): Protocol and statistical analysis plan. Crit Care Resusc. 2014; 16: 255-261.
29. Ogunshola OO, Bogdanova AY. Epo and non-hematopoietic cells: What do we know? Methods Mol Biol. 2013; 982: 13-41.
30. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Brit J Haematol. 2008; 141: 14-31.
31. Corwin HL, Napolitano LM. Erythropoietin for critically ill trauma patients: A missed opportunity? J Trauma Acute Care Surg. 2014; 77: 774-779.
32. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003; 100: 4802-4806.
33. Ozawa T, Toba K, Suzuki H, et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction: Randomized controlled pilot trial of EPO/AMI-1 study. Circulation. 2010; 74: 1415-1423.
34. Sepodes B, Maio R, Pinto R, et al. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transplant Int. 2006; 19: 919-926.
35. Solling C, Christensen AT, Krag S, et al. Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischemia-reperfusion injury. Acta Anaesth Scand. 2011; 55: 185-195.
36. Wu H, Ren B, Zhu J, et al. Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. Eur J Cardio-Thorac. 2006; 29: 902-907.
37. Joyeux-Faure M, Durand M, Bedague D, et al. Evaluation of the effect of one large dose of erythropoietin against cardiac and cerebral ischemic injury occurring during cardiac surgery with cardiopulmonary bypass: A randomized double-blind placebo-controlled pilot study. Fundam Clin Pharm. 2012; 26: 761-770.
38. Hojman P, Taudorf S, Lundby C, et al. Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans. Cytokine. 2009; 45: 154-157.
39. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014; 46: 678-684.
40. Menon D, Maas AE. Erythropoietin in traumatic brain injury: Two strikes...but still not out? Lancet. 2015; 386: 2452-2453.